Vectura Group plc Vectura signs agreement with Aerami Therapeutics
08 Giugno 2020 - 2:15PM
RNS Non-Regulatory
TIDMVEC
Vectura Group plc
08 June 2020
Vectura signs agreement with Aerami Therapeutics Inc.
Agreement to support the development of inhaled imatinib (VR325)
for the treatment of Pulmonary Arterial Hypertension
Chippenham, UK - 8 June 2020 : Vectura Group plc (LSE: VEC)
("Vectura"), an industry leading inhalation CDMO, today announces
the signing of a global licence and development agreement with
Aerami Therapeutics Inc. ("Aerami") for inhaled imatinib (VR325)
for the treatment of Pulmonary Arterial Hypertension.
Aerami will be responsible for the overall development and
commercialisation of inhaled imatinib, with Vectura providing
development services expertise and a license to its FOX (R) mesh
nebuliser technology.
Under the partnership, Vectura will receive development fees,
revenue from the provision of FOX(R) nebuliser devices and
mid-single digit royalties from global net sales of imatinib,
together with regulatory and success-related milestone payments.
There is no upfront payment.
VR325, inhaled imatinib, was first developed by Vectura as part
of its former speciality pharma pipeline. As the company pivoted to
a strategy focused on the CDMO market, it announced it would cease
further investment in this portfolio, instead providing development
services to a more diverse range of biotech and pharmaceutical
companies in the growing inhalation CDMO space.
Today's announcement provides an opportunity for Vectura to
realise value from its historical research and investment in VR325,
whilst also securing new CDMO development services revenue from the
product's further development with Aerami.
Will Downie , Chief Executive Officer of Vectura, commented :
"Pulmonary Arterial Hypertension is a rare, progressive, fatal
disease with approximately 500-1000 new cases diagnosed each year
in the U.S. alone according to the National Organization for Rare
Disorders(1) . In working together with Aerami, this programme has
the potential to impact the lives of patients around the world. Our
deep inhalation expertise, especially now as a CDMO, perfectly
complements the scientific capability of Aerami in the
biotechnology field. We look forward to developing a strong
partnership for years to come."
(1) rarediseases.org/rare-diseases/pulmonary-arterial-hypertension/
- Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700
About Vectura
Vectura is a provider of innovative inhaled drug delivery
services that enable partners to bring their medicines to patients.
With differentiated proprietary technology and pharmaceutical
development expertise, Vectura is one of the few companies globally
with the device, formulation and development capabilities to
deliver a broad range of complex inhaled therapies.
Vectura has eleven key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com
About Aerami
Aerami Therapeutics is a biopharmaceutical company committed to
developing inhaled therapies for treatment of pulmonary arterial
hypertension and other severe respiratory diseases. Aerami's drug
device platform consists of drug aerosol formulations and
cutting-edge technology that allows for precise and fast drug
delivery into the small airway of the lungs.
Anne Whittaker, a non-executive director of Vectura, is the CEO
of Aerami and, accordingly, as part of the authorisation of
allowing the matter to proceed, did not participate in the
deliberations or decisions making around the terms of the
transaction either at Vectura or at Aerami.
Forward-looking statements
This press release contains forward-looking statements,
including statements about the commercialisation of products.
Various risks may cause Vectura's actual results to differ
materially from those expressed or implied by the forward looking
statements, including: commercial limitations imposed by patents
owned or controlled by third parties; dependence upon strategic
alliance partners to develop and commercialise products and
services; difficulties or delays in obtaining regulatory approvals
to market products and services resulting from development efforts;
the requirement for substantial funding to conduct research and
development and to expand commercialisation activities; and product
initiatives by competitors. As a result of these factors,
prospective investors are cautioned not to rely on any
forward-looking statements. We disclaim any intention or obligation
to update or revise any forward looking statements, whether as a
result of new information, future events or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKVLBBBQLFBBB
(END) Dow Jones Newswires
June 08, 2020 08:15 ET (12:15 GMT)
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Apr 2023 a Apr 2024
